Loading…
Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression
Background: Oxidative stress plays an important role in multiple sclerosis (MS). Isoprostanes are biomarkers for oxidative stress and have been related to neurological disease progression. Objective: To study whether plasma isoprostane levels were related to disease progression in MS. Methods: Plasm...
Saved in:
| Published in: | Multiple sclerosis 2012-08, Vol.18 (8), p.1092-1098 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c395t-7371972130559241fbf2e86cd1e3ad1242bbdd31eba5f6a8604b5c1cef62ee243 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c395t-7371972130559241fbf2e86cd1e3ad1242bbdd31eba5f6a8604b5c1cef62ee243 |
| container_end_page | 1098 |
| container_issue | 8 |
| container_start_page | 1092 |
| container_title | Multiple sclerosis |
| container_volume | 18 |
| creator | Teunissen, CE Sombekke, M van Winsen, L Killestein, J Barkhof, F Polman, CH Dijkstra, CD Blankenstein, MA Pratico, D |
| description | Background:
Oxidative stress plays an important role in multiple sclerosis (MS). Isoprostanes are biomarkers for oxidative stress and have been related to neurological disease progression.
Objective:
To study whether plasma isoprostane levels were related to disease progression in MS.
Methods:
Plasma levels of 8,12-iso-iPF2alpha-VI were determined in 17 patients with clinically isolated syndrome (CIS), 41 relapsing–remitting MS (RRMS) patients and 5 primary progressive MS (PPMS) patients and related to MRI and clinical disease parameters.
Results:
Isoprostane levels were similar in CIS (60.9, interquartile range (IQR): 47.7–77.7 pg/ml) and RRMS patients (65.3, IQR: 51.9–82.8 pg/ml). The plasma levels were lower in PPMS patients (42.5, IQR: 37.1–49.9) pg/ml, p |
| doi_str_mv | 10.1177/1352458511433306 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1027042929</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1352458511433306</sage_id><sourcerecordid>2771936131</sourcerecordid><originalsourceid>FETCH-LOGICAL-c395t-7371972130559241fbf2e86cd1e3ad1242bbdd31eba5f6a8604b5c1cef62ee243</originalsourceid><addsrcrecordid>eNp1kc2LFDEQxYMo7rp69yQBETwYzWcnfZTF1YEFPajXJp2uHrOk022qe8Gj_7kZZvxgwVOFql-9V-ER8lTw10JY-0YoI7VxRgitlOLNPXIutLWMt5bfr-86Zof5GXmEeMM5t1aZh-RMyqY1Rrlz8nOXQwGPMNAleZw8da-EZBFnFj9dSZ-Wb57Rrzua4BYS0phpgeQXjHlPpy2tcUlAMSQoM0aki18j5BWpL0DzvNKlwBDDGm-BziMdIh7ManfeF0CMc35MHow-ITw51Qvy5erd58sP7Prj-93l22sWVGtWZpUVrZVCcWNaqcXYjxJcEwYByg9Catn3w6AE9N6MjXcN170JIsDYSACp1QV5edSt3t83wLWbIgZIyWeYN-wEl5Zr2cq2os_voDfzVnK9rlKOW82dcJXiRyrUr2OBsVtKnHz5UaHuEE93N5668uwkvPUTDH8WfudRgRcnwGPwaSw-h4h_uUYqZd1BiB059Hv497r_GP8Cw7-j_A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1080740818</pqid></control><display><type>article</type><title>Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression</title><source>SAGE</source><creator>Teunissen, CE ; Sombekke, M ; van Winsen, L ; Killestein, J ; Barkhof, F ; Polman, CH ; Dijkstra, CD ; Blankenstein, MA ; Pratico, D</creator><creatorcontrib>Teunissen, CE ; Sombekke, M ; van Winsen, L ; Killestein, J ; Barkhof, F ; Polman, CH ; Dijkstra, CD ; Blankenstein, MA ; Pratico, D</creatorcontrib><description>Background:
Oxidative stress plays an important role in multiple sclerosis (MS). Isoprostanes are biomarkers for oxidative stress and have been related to neurological disease progression.
Objective:
To study whether plasma isoprostane levels were related to disease progression in MS.
Methods:
Plasma levels of 8,12-iso-iPF2alpha-VI were determined in 17 patients with clinically isolated syndrome (CIS), 41 relapsing–remitting MS (RRMS) patients and 5 primary progressive MS (PPMS) patients and related to MRI and clinical disease parameters.
Results:
Isoprostane levels were similar in CIS (60.9, interquartile range (IQR): 47.7–77.7 pg/ml) and RRMS patients (65.3, IQR: 51.9–82.8 pg/ml). The plasma levels were lower in PPMS patients (42.5, IQR: 37.1–49.9) pg/ml, p<0.05) compared to CIS and RRMS patients in this cohort, which was not confirmed in a second cohort. Baseline isoprostane levels were not related to clinical progression defined by conversion form CIS to RRMS or change in Expanded Disability Status Scale (EDSS) or MS Functional Composite (MSFC) scores during six years of follow-up (CIS + RRMS), nor to change in volume of gadolinium enhancing lesions, T2 lesion load or T1 hypointense lesion load during 2.8 years of follow-up (CIS + RRMS).
Conclusion:
These results do not support a strong role of 8,12-iso-iPF2alpha-VI in the prediction of disease progression in MS.</description><identifier>ISSN: 1352-4585</identifier><identifier>EISSN: 1477-0970</identifier><identifier>DOI: 10.1177/1352458511433306</identifier><identifier>PMID: 22695538</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Adult ; Biological and medical sciences ; Biomarkers - blood ; Biomarkers - cerebrospinal fluid ; Contrast Media ; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases ; Demyelinating Diseases - blood ; Demyelinating Diseases - diagnosis ; Dinoprost - analogs & derivatives ; Dinoprost - blood ; Dinoprost - cerebrospinal fluid ; Disability Evaluation ; Disease Progression ; Female ; Humans ; Longitudinal Studies ; Magnetic Resonance Imaging ; Male ; Medical sciences ; Middle Aged ; Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis ; Multiple Sclerosis, Chronic Progressive - blood ; Multiple Sclerosis, Chronic Progressive - diagnosis ; Multiple Sclerosis, Relapsing-Remitting - blood ; Multiple Sclerosis, Relapsing-Remitting - cerebrospinal fluid ; Multiple Sclerosis, Relapsing-Remitting - diagnosis ; Multiple Sclerosis, Relapsing-Remitting - pathology ; Netherlands ; Neurology ; Predictive Value of Tests ; Prognosis ; Time Factors ; Up-Regulation</subject><ispartof>Multiple sclerosis, 2012-08, Vol.18 (8), p.1092-1098</ispartof><rights>The Author(s) 2012</rights><rights>2015 INIST-CNRS</rights><rights>SAGE Publications © Aug 2012</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c395t-7371972130559241fbf2e86cd1e3ad1242bbdd31eba5f6a8604b5c1cef62ee243</citedby><cites>FETCH-LOGICAL-c395t-7371972130559241fbf2e86cd1e3ad1242bbdd31eba5f6a8604b5c1cef62ee243</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925,79364</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26233786$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22695538$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Teunissen, CE</creatorcontrib><creatorcontrib>Sombekke, M</creatorcontrib><creatorcontrib>van Winsen, L</creatorcontrib><creatorcontrib>Killestein, J</creatorcontrib><creatorcontrib>Barkhof, F</creatorcontrib><creatorcontrib>Polman, CH</creatorcontrib><creatorcontrib>Dijkstra, CD</creatorcontrib><creatorcontrib>Blankenstein, MA</creatorcontrib><creatorcontrib>Pratico, D</creatorcontrib><title>Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression</title><title>Multiple sclerosis</title><addtitle>Mult Scler</addtitle><description>Background:
Oxidative stress plays an important role in multiple sclerosis (MS). Isoprostanes are biomarkers for oxidative stress and have been related to neurological disease progression.
Objective:
To study whether plasma isoprostane levels were related to disease progression in MS.
Methods:
Plasma levels of 8,12-iso-iPF2alpha-VI were determined in 17 patients with clinically isolated syndrome (CIS), 41 relapsing–remitting MS (RRMS) patients and 5 primary progressive MS (PPMS) patients and related to MRI and clinical disease parameters.
Results:
Isoprostane levels were similar in CIS (60.9, interquartile range (IQR): 47.7–77.7 pg/ml) and RRMS patients (65.3, IQR: 51.9–82.8 pg/ml). The plasma levels were lower in PPMS patients (42.5, IQR: 37.1–49.9) pg/ml, p<0.05) compared to CIS and RRMS patients in this cohort, which was not confirmed in a second cohort. Baseline isoprostane levels were not related to clinical progression defined by conversion form CIS to RRMS or change in Expanded Disability Status Scale (EDSS) or MS Functional Composite (MSFC) scores during six years of follow-up (CIS + RRMS), nor to change in volume of gadolinium enhancing lesions, T2 lesion load or T1 hypointense lesion load during 2.8 years of follow-up (CIS + RRMS).
Conclusion:
These results do not support a strong role of 8,12-iso-iPF2alpha-VI in the prediction of disease progression in MS.</description><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Biomarkers - blood</subject><subject>Biomarkers - cerebrospinal fluid</subject><subject>Contrast Media</subject><subject>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</subject><subject>Demyelinating Diseases - blood</subject><subject>Demyelinating Diseases - diagnosis</subject><subject>Dinoprost - analogs & derivatives</subject><subject>Dinoprost - blood</subject><subject>Dinoprost - cerebrospinal fluid</subject><subject>Disability Evaluation</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Humans</subject><subject>Longitudinal Studies</subject><subject>Magnetic Resonance Imaging</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis</subject><subject>Multiple Sclerosis, Chronic Progressive - blood</subject><subject>Multiple Sclerosis, Chronic Progressive - diagnosis</subject><subject>Multiple Sclerosis, Relapsing-Remitting - blood</subject><subject>Multiple Sclerosis, Relapsing-Remitting - cerebrospinal fluid</subject><subject>Multiple Sclerosis, Relapsing-Remitting - diagnosis</subject><subject>Multiple Sclerosis, Relapsing-Remitting - pathology</subject><subject>Netherlands</subject><subject>Neurology</subject><subject>Predictive Value of Tests</subject><subject>Prognosis</subject><subject>Time Factors</subject><subject>Up-Regulation</subject><issn>1352-4585</issn><issn>1477-0970</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNp1kc2LFDEQxYMo7rp69yQBETwYzWcnfZTF1YEFPajXJp2uHrOk022qe8Gj_7kZZvxgwVOFql-9V-ER8lTw10JY-0YoI7VxRgitlOLNPXIutLWMt5bfr-86Zof5GXmEeMM5t1aZh-RMyqY1Rrlz8nOXQwGPMNAleZw8da-EZBFnFj9dSZ-Wb57Rrzua4BYS0phpgeQXjHlPpy2tcUlAMSQoM0aki18j5BWpL0DzvNKlwBDDGm-BziMdIh7ManfeF0CMc35MHow-ITw51Qvy5erd58sP7Prj-93l22sWVGtWZpUVrZVCcWNaqcXYjxJcEwYByg9Catn3w6AE9N6MjXcN170JIsDYSACp1QV5edSt3t83wLWbIgZIyWeYN-wEl5Zr2cq2os_voDfzVnK9rlKOW82dcJXiRyrUr2OBsVtKnHz5UaHuEE93N5668uwkvPUTDH8WfudRgRcnwGPwaSw-h4h_uUYqZd1BiB059Hv497r_GP8Cw7-j_A</recordid><startdate>20120801</startdate><enddate>20120801</enddate><creator>Teunissen, CE</creator><creator>Sombekke, M</creator><creator>van Winsen, L</creator><creator>Killestein, J</creator><creator>Barkhof, F</creator><creator>Polman, CH</creator><creator>Dijkstra, CD</creator><creator>Blankenstein, MA</creator><creator>Pratico, D</creator><general>SAGE Publications</general><general>Sage Publications</general><general>Sage Publications Ltd</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20120801</creationdate><title>Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression</title><author>Teunissen, CE ; Sombekke, M ; van Winsen, L ; Killestein, J ; Barkhof, F ; Polman, CH ; Dijkstra, CD ; Blankenstein, MA ; Pratico, D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c395t-7371972130559241fbf2e86cd1e3ad1242bbdd31eba5f6a8604b5c1cef62ee243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Biomarkers - blood</topic><topic>Biomarkers - cerebrospinal fluid</topic><topic>Contrast Media</topic><topic>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</topic><topic>Demyelinating Diseases - blood</topic><topic>Demyelinating Diseases - diagnosis</topic><topic>Dinoprost - analogs & derivatives</topic><topic>Dinoprost - blood</topic><topic>Dinoprost - cerebrospinal fluid</topic><topic>Disability Evaluation</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Humans</topic><topic>Longitudinal Studies</topic><topic>Magnetic Resonance Imaging</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis</topic><topic>Multiple Sclerosis, Chronic Progressive - blood</topic><topic>Multiple Sclerosis, Chronic Progressive - diagnosis</topic><topic>Multiple Sclerosis, Relapsing-Remitting - blood</topic><topic>Multiple Sclerosis, Relapsing-Remitting - cerebrospinal fluid</topic><topic>Multiple Sclerosis, Relapsing-Remitting - diagnosis</topic><topic>Multiple Sclerosis, Relapsing-Remitting - pathology</topic><topic>Netherlands</topic><topic>Neurology</topic><topic>Predictive Value of Tests</topic><topic>Prognosis</topic><topic>Time Factors</topic><topic>Up-Regulation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Teunissen, CE</creatorcontrib><creatorcontrib>Sombekke, M</creatorcontrib><creatorcontrib>van Winsen, L</creatorcontrib><creatorcontrib>Killestein, J</creatorcontrib><creatorcontrib>Barkhof, F</creatorcontrib><creatorcontrib>Polman, CH</creatorcontrib><creatorcontrib>Dijkstra, CD</creatorcontrib><creatorcontrib>Blankenstein, MA</creatorcontrib><creatorcontrib>Pratico, D</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Multiple sclerosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Teunissen, CE</au><au>Sombekke, M</au><au>van Winsen, L</au><au>Killestein, J</au><au>Barkhof, F</au><au>Polman, CH</au><au>Dijkstra, CD</au><au>Blankenstein, MA</au><au>Pratico, D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression</atitle><jtitle>Multiple sclerosis</jtitle><addtitle>Mult Scler</addtitle><date>2012-08-01</date><risdate>2012</risdate><volume>18</volume><issue>8</issue><spage>1092</spage><epage>1098</epage><pages>1092-1098</pages><issn>1352-4585</issn><eissn>1477-0970</eissn><abstract>Background:
Oxidative stress plays an important role in multiple sclerosis (MS). Isoprostanes are biomarkers for oxidative stress and have been related to neurological disease progression.
Objective:
To study whether plasma isoprostane levels were related to disease progression in MS.
Methods:
Plasma levels of 8,12-iso-iPF2alpha-VI were determined in 17 patients with clinically isolated syndrome (CIS), 41 relapsing–remitting MS (RRMS) patients and 5 primary progressive MS (PPMS) patients and related to MRI and clinical disease parameters.
Results:
Isoprostane levels were similar in CIS (60.9, interquartile range (IQR): 47.7–77.7 pg/ml) and RRMS patients (65.3, IQR: 51.9–82.8 pg/ml). The plasma levels were lower in PPMS patients (42.5, IQR: 37.1–49.9) pg/ml, p<0.05) compared to CIS and RRMS patients in this cohort, which was not confirmed in a second cohort. Baseline isoprostane levels were not related to clinical progression defined by conversion form CIS to RRMS or change in Expanded Disability Status Scale (EDSS) or MS Functional Composite (MSFC) scores during six years of follow-up (CIS + RRMS), nor to change in volume of gadolinium enhancing lesions, T2 lesion load or T1 hypointense lesion load during 2.8 years of follow-up (CIS + RRMS).
Conclusion:
These results do not support a strong role of 8,12-iso-iPF2alpha-VI in the prediction of disease progression in MS.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>22695538</pmid><doi>10.1177/1352458511433306</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1352-4585 |
| ispartof | Multiple sclerosis, 2012-08, Vol.18 (8), p.1092-1098 |
| issn | 1352-4585 1477-0970 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1027042929 |
| source | SAGE |
| subjects | Adult Biological and medical sciences Biomarkers - blood Biomarkers - cerebrospinal fluid Contrast Media Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases Demyelinating Diseases - blood Demyelinating Diseases - diagnosis Dinoprost - analogs & derivatives Dinoprost - blood Dinoprost - cerebrospinal fluid Disability Evaluation Disease Progression Female Humans Longitudinal Studies Magnetic Resonance Imaging Male Medical sciences Middle Aged Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis Multiple Sclerosis, Chronic Progressive - blood Multiple Sclerosis, Chronic Progressive - diagnosis Multiple Sclerosis, Relapsing-Remitting - blood Multiple Sclerosis, Relapsing-Remitting - cerebrospinal fluid Multiple Sclerosis, Relapsing-Remitting - diagnosis Multiple Sclerosis, Relapsing-Remitting - pathology Netherlands Neurology Predictive Value of Tests Prognosis Time Factors Up-Regulation |
| title | Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T16%3A51%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Increased%20plasma%208,12-iso-iPF2alpha-%20VI%20levels%20in%20relapsing%20multiple%20sclerosis%20patients%20are%20not%20predictive%20of%20disease%20progression&rft.jtitle=Multiple%20sclerosis&rft.au=Teunissen,%20CE&rft.date=2012-08-01&rft.volume=18&rft.issue=8&rft.spage=1092&rft.epage=1098&rft.pages=1092-1098&rft.issn=1352-4585&rft.eissn=1477-0970&rft_id=info:doi/10.1177/1352458511433306&rft_dat=%3Cproquest_cross%3E2771936131%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c395t-7371972130559241fbf2e86cd1e3ad1242bbdd31eba5f6a8604b5c1cef62ee243%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1080740818&rft_id=info:pmid/22695538&rft_sage_id=10.1177_1352458511433306&rfr_iscdi=true |